Details for Patent: 11,426,378

Which drugs does patent 11,426,378 protect, and when does it expire?

Patent 11,426,378 protects EPSOLAY and is included in one NDA.

This patent has twelve patent family members in two countries.

Summary for Patent: 11,426,378

Title:	Method for long-term treatment of rosacea
Abstract:	A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in the pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75%.
Inventor(s):	Ofer Toledano, Ofra Levy-Hacham, Ori NOV, Vered RAM
Assignee:	Mayne Pharma LLC
Application Number:	US16/794,887
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Delivery;

Drugs Protected by US Patent 11,426,378

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes	11,426,378					TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER

International Family Members for US Patent 11,426,378

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3130362
Canada	3130437
Canada	3130439
Canada	3130441